HC Wainwright Has Negative Outlook of MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a report released on Monday, March 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.43 for the year, down from their previous forecast of $0.46. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Trading Down 16.4 %

Shares of Milestone Pharmaceuticals stock opened at $1.99 on Wednesday. The company’s 50-day moving average price is $2.02 and its 200-day moving average price is $1.81. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The company has a market cap of $106.12 million, a price-to-earnings ratio of -2.46 and a beta of 1.83.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp grew its position in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares in the last quarter. National Bank of Canada FI grew its position in Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares in the last quarter. PVG Asset Management Corp purchased a new position in Milestone Pharmaceuticals during the third quarter worth about $46,000. Atria Investments Inc increased its stake in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $73,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.